APA (7th ed.) Citation

JP, F., G, G., E, J., J, M., MA, T., DC, S., . . . AL, P. (2020). Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial. Diabetes, obesity & metabolism, 22(7), 1083. https://doi.org/10.1111/dom.13997

Chicago Style (17th ed.) Citation

JP, Frias, Gonzalez-Galvez G, Johnsson E, Maaske J, Testa MA, Simonson DC, Dronamraju N, Garcia-Sanchez R, and Peters AL. "Efficacy and Safety of Dual Add-on Therapy with Dapagliflozin Plus Saxagliptin Versus Glimepiride in Patients with Poorly Controlled Type 2 Diabetes on a Stable Dose of Metformin: Results from a 52-week, Randomized, Active-controlled Trial." Diabetes, Obesity & Metabolism 22, no. 7 (2020): 1083. https://doi.org/10.1111/dom.13997.

MLA (9th ed.) Citation

JP, Frias, et al. "Efficacy and Safety of Dual Add-on Therapy with Dapagliflozin Plus Saxagliptin Versus Glimepiride in Patients with Poorly Controlled Type 2 Diabetes on a Stable Dose of Metformin: Results from a 52-week, Randomized, Active-controlled Trial." Diabetes, Obesity & Metabolism, vol. 22, no. 7, 2020, p. 1083, https://doi.org/10.1111/dom.13997.